EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Resolutions to cancel the share premium account of the Company and to grant the Company the general authority to make market purchases of its own shares were passed.
Notification of major holdings.
The Company is pleased to announce that the trading in the second quarter of the year has continued the favourable trends experienced in the first quarter.
EKF Diagnostics announces that a general meeting of the Company will be held on 27th July 2017.
EKF Diagnostics announces that 21,614,766 share options over ordinary shares have been cancelled.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, wishes to update shareholders on its current trading and the proposals it set out in its announcement on 20 March 2017.